Aptamers have emerged as a transformative technology in biotechnology, diagnostics, therapeutics and molecular research. These short, single-stranded nucleic acid molecules are engineered to bind specific targets with high affinity and specificity, making them valuable alternatives to antibodies in numerous applications. As innovation in aptamer technology accelerates, securing robust patent protection has become increasingly important for biotechnology companies, research institutions and pharmaceutical organizations.
One of the most critical aspects of preparing an aptamer patent application is complying with nucleic acid sequence listing requirements. Patent offices worldwide – including the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), the Japan Patent Office (JPO) and the World Intellectual Property Organization (WIPO) for Patent Cooperation Treaty (PCT) applications – require standardized sequence listings for inventions involving nucleotide or amino acid sequences.
Failure to prepare sequence listings correctly can result in formal objections, processing delays, additional filing costs, or even jeopardize the scope of patent protection. This guide explains sequence listing requirements for aptamer patent applications, international standards, formatting rules and best practices for successful filings.
What Is an Aptamer?
An aptamer is a short, synthetic nucleic acid sequence composed of DNA, RNA, or chemically modified nucleotides that folds into a unique three-dimensional structure capable of binding a specific molecular target.
Aptamers are commonly developed to recognize:
- Proteins
- Peptides
- Small molecules
- Viruses
- Bacteria
- Cells
- Biomarkers
- Enzymes
- Growth factors
- Metal ions
Their high specificity, stability and ease of chemical synthesis have made aptamers valuable in diagnostics, drug delivery, biosensors, personalized medicine and targeted therapeutics.
Why Sequence Listings Are Required
Patent offices require standardized sequence listings to enable efficient examination, publication and electronic searching of biological sequence information.
A sequence listing provides a structured representation of nucleotide and amino acid sequences disclosed in a patent application. It allows patent examiners and the public to identify and compare biological sequences using consistent formats.
For aptamer inventions, sequence listings help define the claimed nucleic acid molecules and support the written description of the invention.
International Sequence Listing Standard: WIPO ST.26
Most new patent applications containing nucleotide or amino acid sequences must comply with WIPO Standard ST.26, which replaced the earlier ST.25 standard for applicable filings.
ST.26 establishes a harmonized XML-based format for sequence listings used by participating patent offices, including those accepting PCT applications. It standardizes how sequence data, sequence features and associated information are submitted electronically.
Applicants should confirm the applicable filing date and the requirements of the receiving office, as legacy applications filed before the transition may still be governed by ST.25 rules.
When Is a Sequence Listing Required?
A sequence listing is generally required when a patent application discloses nucleotide or amino acid sequences that meet the applicable threshold under the governing standard.
For aptamer-related inventions, this commonly includes:
- DNA aptamer sequences
- RNA aptamer sequences
- Synthetic oligonucleotides
- Modified nucleic acid sequences (where reportable under the standard)
- Functional sequence variants
- Engineered binding sequences
Whether chemically modified nucleotides or other specialized molecules require inclusion depends on the applicable ST.26 rules and how the sequence is represented.
Components of an ST.26 Sequence Listing
An ST.26 sequence listing typically includes structured information such as:
- Sequence identification number
- Molecule type
- Sequence length
- Organism designation (or “Artificial Sequence,” where appropriate)
- Sequence data
- Feature annotations
- Qualifiers
- Modification information (where applicable)
The listing is submitted as an XML file that complies with the ST.26 schema.
Identifying Artificial Aptamer Sequences
Because many aptamers are generated through in vitro selection methods rather than isolated from naturally occurring organisms, they are commonly identified as artificial sequences in sequence listings.
Applicants should ensure that the designation and accompanying metadata comply with the applicable ST.26 rules and accurately reflect the origin of the sequence.
Reporting Modified Nucleotides
Many commercially valuable aptamers include chemical modifications that improve stability, binding affinity, or resistance to nucleases.
Examples include:
- 2′-Fluoro modifications
- 2′-O-methyl modifications
- Locked nucleic acids (LNA)
- Phosphorothioate linkages
- PEG conjugation
- Other synthetic nucleotide analogs
ST.26 includes specific rules for representing certain modified residues and sequence features. Applicants should ensure that modifications are reported in accordance with the standard and are fully described in the specification where relevant.
Functional Variants and Sequence Scope
Patent applications frequently disclose multiple aptamer variants to support broader claim coverage.
These may include:
- Conservative substitutions
- Truncated sequences
- Extended sequences
- Mutated variants
- Optimized binding sequences
- Families of related aptamers
Each disclosed sequence that satisfies the reporting requirements should be evaluated for inclusion in the sequence listing. Broad claims should also be supported by an adequate written description and enablement.
Relationship Between the Sequence Listing and the Specification
The sequence listing supplements – but does not replace – the written patent specification.
The specification should clearly describe:
- The aptamer and its intended use
- Target molecules
- Selection methods (for example, SELEX where applicable)
- Binding characteristics
- Experimental data
- Therapeutic or diagnostic applications
- Sequence modifications
- Functional properties
The sequence listing should correspond accurately with the disclosure in the specification and sequence identifiers should be used consistently throughout the application.
File Format Requirements
For applications subject to ST.26, sequence listings are submitted as XML files.
Applicants should verify that:
- The XML validates against the ST.26 schema.
- Sequence identifiers are consistent.
- Feature annotations are complete where required.
- Metadata complies with the applicable standard.
- The file is free of formatting and validation errors.
Many patent offices provide or recommend software tools to assist with preparing compliant sequence listings.
Common Mistakes in Aptamer Sequence Listings
Errors in sequence listings can lead to formal objections or requests for correction.
Common issues include:
- Incorrect sequence identifiers
- Inconsistent sequence numbering
- Missing reportable sequences
- XML validation errors
- Incorrect molecule type
- Inaccurate feature annotations
- Discrepancies between the sequence listing and the specification
- Improper handling of modified residues
- Incomplete metadata
Careful review before filing can help avoid unnecessary delays.
Supporting Broad Patent Claims
For applicants seeking broad protection, it is often beneficial to disclose:
- Multiple aptamer embodiments
- Functional sequence variants
- Binding motifs
- Target-binding regions
- Experimental examples
- Performance data
- Alternative chemical modifications
A robust disclosure can strengthen support for broader claims, provided it satisfies the applicable patent law requirements in the relevant jurisdiction.
International Filing Considerations
Many aptamer developers pursue patent protection in multiple jurisdictions.
Because participating patent offices increasingly rely on the ST.26 standard, preparing a compliant sequence listing at the outset can streamline:
- PCT applications
- National phase entries
- Regional patent filings
- International prosecution
Applicants should still review any office-specific procedural requirements, as filing practices may vary.
Best Practices for Aptamer Patent Applications
To improve the quality and efficiency of an aptamer patent filing:
- Prepare the sequence listing early in the drafting process.
- Validate ST.26 XML files before submission.
- Maintain consistency between sequence identifiers and the specification.
- Clearly describe all relevant sequence modifications.
- Include experimental support for claimed functionality where available.
- Review all disclosed variants for reportability.
- Coordinate closely with patent counsel and sequence listing specialists.
These practices can reduce prosecution delays and improve the overall quality of the patent application.
Final Thoughts
Aptamer innovations continue to drive advances in precision medicine, molecular diagnostics, biosensors and targeted therapeutics. As these technologies become increasingly valuable, well-prepared patent applications are essential for securing meaningful intellectual property protection.
Complying with modern nucleic acid sequence listing requirements – particularly the ST.26 XML standard where applicable – is a key part of that process. Accurate sequence listings, consistent technical disclosures and careful attention to filing requirements help reduce formal objections, support efficient patent examination and strengthen the foundation for global patent protection.
For biotechnology companies and research organizations developing aptamer-based technologies, investing time in preparing compliant sequence listings is an important step toward protecting valuable scientific innovations and maximizing long-term commercial opportunities.